MHRA's Xeal clopidogrel recall shows how a formulation error can sweep up every batch

What happened

On 26 October 2026 the MHRA announced a Class 2 recall covering every batch of Xeal Pharma's unlicensed clopidogrel oral solution and suspension produced before notification. The alert cites a formulation error linked to a 76% potency figure. The URL indicates that all strengths are included, and the record says patients are to be traced and reviewed.

Two details matter. First, the recall is not limited to named lots. It covers everything made before the company was notified, which suggests the problem sits in the formulation or process rather than in a single batch. Second, the instruction to trace and review patients means this is not only a pharmacy shelf-clearance exercise. The summary does not say in which direction the potency deviated. It also does not give the number of affected patients, the cause of the error or any reported harm. Those points are not yet known from the available record, and readers should check the full MHRA alert before drawing conclusions.

Why a formulation error is a quality-system issue

A potency problem in a finished product is rarely just an analytical result. A formulation error points upstream to the master formula, calculations, raw material handling, in-process checks and release testing. If the error affected every batch, any review has to ask why routine release controls did not catch it, or whether the testing was not designed to detect it.

Clopidogrel is an antiplatelet medicine, so dose accuracy is central to how the product is used. That is general context rather than a statement about outcomes here. The records report no patient harm, and none should be assumed.

For QPs and quality heads at any manufacturer of liquid preparations, the lesson is practical. A recall that covers every batch signals that the failure was systemic. It is worth asking whether your own release strategy would detect a consistent formulation error, or only a batch-to-batch deviation.

Regulatory context: unlicensed liquids and Class 2 recalls

The recalled products are unlicensed. In the UK, unlicensed medicines are generally supplied outside the marketing authorisation route to meet individual patient needs, often where no suitable licensed form exists. Oral liquids of established tablet medicines are a common example. Because such products have no authorisation dossier behind them, the manufacturer's quality system and the prescriber's and pharmacist's checks carry more of the assurance burden.

Under the MHRA's classification, a Class 2 recall is one where defective product could cause mistreatment or harm, but the risk is not judged to be life-threatening or serious enough for the most urgent class. Recall classification is a risk judgement. It does not mean the problem is minor, and here it comes with a requirement to trace and review patients.

A busy week for notices, and a transparency gap

Other records from 28 October show how differently regulators publish safety information. BfArM listed urgent field safety notices for Link's Endo-Model Knee Fusion Nail, Abbott's FreeStyle Libre 3 and Libre apps, Inova's Aptiva CTD Essential Reagent, Elekta's MOSAIQ oncology information system and Zytomed's Rabbit anti-TFE3 reagent. In each case the public entry gives little or nothing on the defect, affected lots or required actions. Those details sit in the manufacturers' attached advisories.

Health Canada's entries were more specific. A Type II recall covers one lot of bioMérieux's BIOFIRE BCID2 Panel after complaints of false negatives, linked to unintended movement of pouch chemistry. Agilent's electronic instructions for PD-L1 IHC 22C3 pharmDx wrongly gave tissue-section thickness and slide-storage temperature for three lots after hyphens were lost in a formatting change. Siemens Healthineers is deploying service pack NX VA60A-SP04, a bug fix, for Magnetom scanners under a Type II recall.

These device and diagnostics cases are a different regime from a medicines recall, and the records do not link them to Xeal. They do share a theme with it: small control failures, such as a formula error, a lost hyphen or a chemistry shift, can have outsized consequences. They also show that a regulator's headline entry is often not enough to act on.

Who is affected and what to watch

The immediate burden falls on dispensing pharmacies, prescribers, and any organisations that procured Xeal's clopidogrel liquids, along with the patients who received them. Wholesalers and specials procurement teams also need to confirm what they supplied and to whom. Teams outside the UK should check whether any product reached their supply chains, though the records do not say it did.

The open questions are the root cause, how many patients were supplied, what alternative supply is available for patients who need an oral liquid, and whether the MHRA takes further action on the manufacturer. None of these is addressed in the records. Follow-up alerts or an update to the MHRA notice are the places to look.